124 related articles for article (PubMed ID: 8599804)
1. New drugs. The anthrapyrazoles.
Gogas H; Mansi JL
Cancer Treat Rev; 1996 Nov; 21(6):541-52. PubMed ID: 8599804
[No Abstract] [Full Text] [Related]
2. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen.
Leteurtre F; Kohlhagen G; Paull KD; Pommier Y
J Natl Cancer Inst; 1994 Aug; 86(16):1239-44. PubMed ID: 8040892
[TBL] [Abstract][Full Text] [Related]
3. Navelbine and the anthrapyrazoles.
Jones AL; Smith IE
Hematol Oncol Clin North Am; 1994 Feb; 8(1):141-52. PubMed ID: 8150775
[TBL] [Abstract][Full Text] [Related]
4. Effects of anthrapyrazole antineoplastic agents on lipid peroxidation.
Frank P; Novak RF
Biochem Biophys Res Commun; 1986 Nov; 140(3):797-807. PubMed ID: 3778486
[TBL] [Abstract][Full Text] [Related]
5. A novel 9-aza-anthrapyrazole effective against human prostatic carcinoma xenografts.
Supino R; Polizzi D; Pavesi R; Pratesi G; Guano F; Capranico G; Palumbo M; Sissi C; Richter S; Beggiolin G; Menta E; Pezzoni G; Spinelli S; Torriani D; Carenini N; Dal Bo L; Facchinetti F; Tortoreto M; Zunino F
Oncology; 2001; 61(3):234-42. PubMed ID: 11574780
[TBL] [Abstract][Full Text] [Related]
6. DNA-interactive anticancer aza-anthrapyrazoles: biophysical and biochemical studies relevant to the mechanism of action.
Sissi C; Moro S; Richter S; Gatto B; Menta E; Spinelli S; Krapcho AP; Zunino F; Palumbo M
Mol Pharmacol; 2001 Jan; 59(1):96-103. PubMed ID: 11125029
[TBL] [Abstract][Full Text] [Related]
7. Anthrapyrazoles and interstitial laser phototherapy for experimental treatment of squamous cell carcinoma.
Graeber IP; Paiva MB; Eshraghi AA; Suh MJ; Castro DJ; Saxton RE
Laryngoscope; 1998 Mar; 108(3):351-7. PubMed ID: 9504606
[TBL] [Abstract][Full Text] [Related]
8. Laser chemotherapy of human carcinoma cells with three new anticancer drugs.
Eshraghi AA; Castro DJ; Paiva MB; Graeber IP; Jongewaard N; Arshadnia S; Lamas G; Soudant J; Saxton RE
J Clin Laser Med Surg; 1997 Feb; 15(1):15-21. PubMed ID: 9467337
[TBL] [Abstract][Full Text] [Related]
9. A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone.
Liang H; Wu X; Guziec LJ; Guziec FS; Larson KK; Lang J; Yalowich JC; Hasinoff BB
J Chem Inf Model; 2006; 46(4):1827-35. PubMed ID: 16859314
[TBL] [Abstract][Full Text] [Related]
10. Potential cardiotoxicity with the use of DuP-941: a case report.
Walsh SM; Walley VM; Chandra L; Huan SD; Veinot JP; Higginson LA
Can J Cardiol; 1995 May; 11(5):419-22. PubMed ID: 7750038
[TBL] [Abstract][Full Text] [Related]
11. A clinical study of nafazatrom in advanced human breast cancer.
Jones AL; Powles TJ; Forgeson GV; Coombes RC
Cancer Chemother Pharmacol; 1991; 27(4):326-8. PubMed ID: 1998990
[TBL] [Abstract][Full Text] [Related]
12. Antitumor potential of aza-bioisosterism in anthracenedione-based drugs.
Sissi C; Palumbo M
Curr Top Med Chem; 2004; 4(2):219-30. PubMed ID: 14754455
[TBL] [Abstract][Full Text] [Related]
13. Interstitial laser photochemotherapy with new anthrapyrazole drugs for the treatment of xenograft tumors.
Paiva MB; Saxton RE; Letts GA; Chung PS; Soudant J; Vanderwerf Q; Castro DJ
J Clin Laser Med Surg; 1995 Oct; 13(5):307-13. PubMed ID: 10163493
[TBL] [Abstract][Full Text] [Related]
14. The effect of the anthrapyrazole antitumour agent CI941 on rat liver microsome and cytochrome P-450 reductase mediated free radical processes. Inhibition of doxorubicin activation in vitro.
Graham MA; Newell DR; Butler J; Hoey B; Patterson LH
Biochem Pharmacol; 1987 Oct; 36(20):3345-51. PubMed ID: 2823819
[TBL] [Abstract][Full Text] [Related]
15. Overview of new treatments for breast cancer.
Hortobagyi GN
Breast Cancer Res Treat; 1992; 21(1):3-13. PubMed ID: 1356516
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study.
Sosman JA; Flaherty LE; Liu PY; Fletcher W; Thompson JA; Hantel A; Sondak V
Invest New Drugs; 1995; 13(1):83-7. PubMed ID: 7499114
[TBL] [Abstract][Full Text] [Related]
17. Comparison of daunorubicin and anthrapyrazolone sensitivity and transport in resistant cell lines.
McGown A; Poppitt DG; Fox BW
Br J Cancer; 1987 Dec; 56(6):752-4. PubMed ID: 3435702
[TBL] [Abstract][Full Text] [Related]
18. Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer.
Talbot DC; Smith IE; Mansi JL; Judson I; Calvert AH; Ashley SE
J Clin Oncol; 1991 Dec; 9(12):2141-7. PubMed ID: 1960556
[TBL] [Abstract][Full Text] [Related]
19. Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin.
Fisher GR; Patterson LH
Cancer Chemother Pharmacol; 1992; 30(6):451-8. PubMed ID: 1394801
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia activated prodrugs of a 9-aza-anthrapyrazole derivative that has promising anticancer activity.
El-Dakdouki MH; Adamski N; Foster L; Hacker MP; Erhardt PW
J Med Chem; 2011 Dec; 54(23):8224-7. PubMed ID: 22011244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
